Arch Therapeutics, Inc. (ARTH)

Arch Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Revenue	0.13	0.08	0.02	0.01	-	-
Revenue Growth (YoY)	324.67%	383.80%	35.34%	-	-	-
Cost of Revenue	0.09	0.08	0.05	0.03	-	-
Gross Profit	0.04	-0	-0.04	-0.01	-	-
Selling, General & Admin	4.01	4.37	4.52	5.01	3.74	3.97
Research & Development	0.75	0.67	1.15	1.35	1.61	2.4
Operating Expenses	4.76	5.04	5.67	6.36	5.35	6.37
Operating Income	-4.71	-5.04	-5.71	-6.38	-5.35	-6.37
Interest Expense	-3.72	-3.1	-0.57	-0.15	-0.02	-
Other Non Operating Income (Expenses)	-	1.16	1	0.11	0.68	1.82
EBT Excluding Unusual Items	-8.43	-6.98	-5.28	-6.42	-4.69	-4.55
Other Unusual Items	-	-	-	0.18	-	-
Pretax Income	-8.43	-6.98	-5.28	-6.24	-4.69	-4.55
Net Income	-8.43	-6.98	-5.28	-6.24	-4.69	-4.55
Net Income to Common	-8.43	-6.98	-5.28	-6.24	-4.69	-4.55
Shares Outstanding (Basic)	5	3	1	1	1	1
Shares Outstanding (Diluted)	5	3	1	1	1	1
Shares Change (YoY)	283.82%	156.27%	9.05%	16.99%	13.05%	8.92%
EPS (Basic)	-1.78	-2.27	-4.40	-5.67	-4.99	-5.47
EPS (Diluted)	-1.78	-2.27	-4.40	-5.67	-4.99	-5.47
Free Cash Flow	-3.69	-3.38	-4.46	-5.96	-5.05	-5.27
Free Cash Flow Per Share	-0.78	-1.10	-3.71	-5.42	-5.37	-6.33
Gross Margin	33.38%	-3.22%	-228.96%	-127.25%	-	-
Operating Margin	-3611.58%	-6661.67%	-36473.33%	-55141.58%	-	-
Free Cash Flow Margin	-2827.86%	-4461.91%	-28469.68%	-51551.26%	-	-
EBITDA	-4.71	-5.04	-5.71	-6.37	-5.35	-6.36
D&A For EBITDA	0	0	0	0	0.01	0.01
EBIT	-4.71	-5.04	-5.71	-6.38	-5.35	-6.37

Source: S&P Capital IQ. Standard template.